FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Meisner Derek M					2. Issuer Name and Ticker or Trading Symbol X4 Pharmaceuticals, Inc [XFOR]									ck all app Direc	ector cer (give title		rson(s) to Is 10% Or Other (wner	
(Last) (First) (Middle) C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 03/24/2021								^	below			below) nsel		
(Street) BOSTON MA 02134 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	5. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)						Execution [3. Transa Code (8)		4. Securities Acquired (ADisposed Of (D) (Instr. 3, 5)		4 and Securit		ies cially Following	Form (D) o	n: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or P	rice		ction(s)			(1130.4)
Common Stock 03/24/2					2021				A		47,728(1) [A	\$ <mark>0</mark>	64,394(2)			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion Date Execution Date or Exercise (Month/Day/Year) if any Price of Derivative		on Date,	Code (Insti				6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) Amour or Numbe of Title Shares		tr.	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

Remarks:

/s/ Derek M. Meisner

03/25/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Represents unvested restricted stock units.